How does the overestimation of patient fears around LAIs impact the decision to present these as a treatment option to patients with schizophrenia?

Long-acting injectables (LAIs) are thought to have a number of advantages over oral antipsychotics (APs), including removing the need for daily administration, improving adherence, and enhancing patient outcomes.¹ However, LAIs remain underutilized relative to oral APs, with one analysis of commercially insured patients finding that oral APs represent 68.1% of prescriptions, compared